Writtika Roy
Psychiatry · Frisco, TXNPI 1366701245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 30 payments — averaging $63.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$372
- Axsome Therapeutics, Inc.$363
- AbbVie$311
- E.r. Squibb & Sons, L.L.C.$137
- Teva Pharmaceuticals USA, Inc.$129
- Supernus Pharmaceuticals, Inc.$115
- plus $476 from 6 others
Across 177 payments — averaging $7182.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$724K
- Biohaven Pharmaceutical Holding Company Ltd.$171K
- F. Hoffmann-la Roche AG$142K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$110K
- Janssen Research & Development, LLC$49K
- Boehringer Ingelheim$49K
- plus $26K from 2 others
What the payments were for
- Food & beverage$1,82396%
- Education$804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 2 | $372 |
| Axsome Therapeutics, Inc. | 4 | $363 |
| AbbVie(2 entities) | 10 | $311 |
| E.r. Squibb & Sons, L.L.C. | 4 | $137 |
| Teva Pharmaceuticals USA, Inc. | 1 | $129 |
| Supernus Pharmaceuticals, Inc. | 1 | $115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $111 |
| Tempus AI, Inc | 1 | $96 |
| Johnson & Johnson | 1 | $94 |
| Genentech, Inc. | 2 | $80 |
| Otsuka America Pharmaceutical, Inc. | 1 | $76 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,903 in reported general payments places this provider in the 75th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 11 | $265 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Frisco
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.